Cell Therapy Logistics Market

What Is the Cell Therapy Logistics Market Size?

The global cell therapy logistics market size was valued at USD 1.81 billion in 2025 and is estimated at USD 2.27 billion in 2026, forecast to reach USD 16.95 billion by 2035, expanding at a 25.05% CAGR between 2026 and 2035. North America leads with approximately 42% share, while Transport Services dominate all other service offerings with approximately 26% share.

We observed that growth is concentrated in commercial-stage distribution and cryogenic temperature handling, with software orchestration and control tower services driving the dominant structural shifts through 2035.

Source: www.nextmsc.com

Market Opportunity: The cell therapy logistics market is expected to create an absolute dollar opportunity of USD 14.68 billion between 2026 and 2035, presenting significant investment potential across cryogenic supply chain infrastructure and patient access services.

According to Next Move Strategy Consulting analysis, logistics providers are increasingly bundling chain of identity and chain of custody software with physical transport and storage services into single-vendor offerings, a shift that favors integrated providers with proprietary orchestration platforms over point-solution vendors as commercial-stage cell therapy volumes scale through 2035.

What Does the Cell Therapy Logistics Market Encompass?

The cell therapy logistics market encompasses the transport, storage, packaging, control tower, patient access, quality and compliance, and software services required to move living cellular material from collection sites through manufacturing and back to patients without compromising chain of identity or chain of custody. Our assessment indicates that the scope spans autologous and allogeneic therapy modalities across the collection, manufacturing transfer, distribution, administration, and reverse logistics workflow stages, serving biopharma companies, CDMOs, hospitals, academic centers, and contract research organizations worldwide.

The market has evolved from ad hoc courier arrangements supporting early clinical trials toward purpose-built cryogenic supply chain networks as regulatory bodies including the U.S. Food and Drug Administration expand approvals for chimeric antigen receptor T-cell and other cellular therapies. We observed that technology adoption is shifting toward orchestration and visibility software that automates chain of custody documentation across multiple handoff points. Next Move Strategy Consulting's analysis indicates that this structural shift, combined with rising commercial-stage therapy approvals, is redefining procurement criteria across the cell therapy logistics market.

Source: www.nextmsc.com

Key Emerging Trends

Based on research conducted by Next Move Strategy Consulting, we found that four structural trends are reshaping cold chain infrastructure, service integration, and patient access across the industry.

How Is Cryogenic Packaging Innovation Transforming Cell Therapy Transport?

Manufacturers are introducing next-generation cryogenic shippers that extend hold time while reducing liquid nitrogen dependency and shipment weight. We observed that Cryoport Systems launched its Cryoport Express Cryogenic HV3 Shipping System in January 2025, expanding its portfolio for transporting temperature-sensitive biologics and cell therapies. Logistics providers are adopting similar next-generation shipper platforms to reduce dry ice and liquid nitrogen dependency while improving shipment reliability across long-haul commercial distribution lanes.

Why Is Orchestration Software Becoming Central to Chain of Custody Management?

Cell therapy developers are increasingly requiring integrated software platforms that automate chain of identity and chain of custody documentation across every handoff point. Our findings suggest that Biocair's integration with TrakCel's OCELLOS orchestration platform enables two-way data exchange that gives stakeholders complete visibility of in-transit orders. Logistics providers are expanding similar software integrations to meet biopharma customers' growing documentation and traceability requirements.

How Is Commercial-Stage Scaling Reshaping Cell Therapy Distribution Networks?

Rising numbers of commercially approved cell and gene therapies are shifting logistics demand from clinical trial shipment volumes toward recurring commercial distribution networks. We observed that Cryoport reported supporting a record 766 global clinical trials and 21 commercially approved cell and gene therapies as of March 2026. Logistics providers are expanding regional supply chain centers to support this transition from clinical to commercial-scale distribution.

What Role Does Quality Certification Play in Cell Therapy Logistics Differentiation?

Formal quality certifications are becoming a differentiating factor as biopharma customers evaluate logistics partners for commercial-stage therapy distribution. Our analysis shows that Cryoport Systems became the first global supply chain company to secure ISO 21973:2020 certification from DNV Business Assurance, establishing benchmarks for safety and traceability in cell and gene therapy logistics. Competing providers are pursuing similar certifications to qualify for large-scale commercial contracts.

ECOSYSTEM ANALYSIS OF THE CELL THERAPY LOGISTICS MARKET

The cell therapy logistics market ecosystem connects research organizations, cell therapy developers, technology partners, cold chain monitoring providers, packaging specialists, transportation networks, and regulatory authorities to enable the safe movement of advanced therapies. Biopharmaceutical companies and CDMOs develop cell therapies, while logistics providers ensure cryogenic storage, temperature-controlled transportation, chain-of-identity, and chain-of-custody management. Regulatory compliance and quality assurance underpin every stage, ensuring product integrity, traceability, and timely delivery from collection through patient administration.

Growth Drivers and Restraints

Growth Catalyst and Risk Assessment Matrix

Source: www.nextmsc.com

What Is the Primary Growth Driver of the Flexibility Platform Market?

Rising FDA and EMA approvals of commercial-stage cell and gene therapies are the primary driver of the market. The U.S. Food and Drug Administration continues to expand its list of approved cellular and gene therapy products, sustaining demand for logistics providers capable of supporting recurring commercial distribution rather than one-off clinical trial shipments. We observed that this regulatory momentum, combined with growing hospital network readiness, continues to anchor baseline logistics demand across developed and emerging cell therapy markets alike.

How Is Battery Storage Commercialization Driving Flexibility Platform Market Growth?

Expanding CAR-T and other autologous therapy clinical trial pipelines are driving market growth toward specialized single-patient chain of custody logistics. Cryoport reported supporting a record 766 global clinical trials as of March 2026, reflecting sustained pipeline expansion across the cell and gene therapy industry. Our assessment indicates that this trial volume growth, combined with rising commercial approvals, is compressing procurement timelines for providers capable of scaling from clinical to commercial distribution.

What Is Restraining Flexibility Platform Market Expansion?

High cost and complexity of cryogenic and time-critical logistics restrain broader market penetration, particularly for smaller biopharma developers with limited logistics budgets. The International Air Transport Association continues to track the specialized handling requirements and cost premiums associated with time- and temperature-sensitive pharmaceutical shipments. We found that this cost structure disproportionately affects academic and smaller CRO customers, who face higher relative logistics costs per patient shipment compared with large commercial-stage biopharma programs.

Segmentation Analysis

Segment Sizing: By Temperature Regime

Source: www.nextmsc.com

Which Temperature Regime Segment Dominates the Cell Therapy Logistics Market?

Cryogenic handling led the market with USD 0.58 billion in 2025, reflecting the storage and transport requirements of most autologous cell therapies that require liquid nitrogen vapor phase conditions to preserve cell viability. We observed that Refrigerated is the fastest-growing temperature regime, expanding at a 27.0% CAGR from 2026 to 2035, as a growing share of allogeneic and next-generation cell therapies adopt less complex cold chain requirements.

Segment Sizing: By Commercial Stage

Source: www.nextmsc.com

Which Commercial Stage Segment Leads Cell Therapy Logistics Market Demand?

Clinical-stage logistics remained the leading commercial stage segment within the market, valued at USD 1.14 billion in 2025, on sustained demand from the industry's large base of active clinical trials. Our findings suggest that Commercial-stage logistics is the fastest-growing segment, registering a 30.8% CAGR from 2026 to 2035, as an increasing number of cell therapies transition from clinical trials to recurring commercial distribution following regulatory approval.

Segment Sizing: By Customer Type

Source: www.nextmsc.com

Which Customer Type Segment Is Most Significant in the Cell Therapy Logistics Market?

Biopharma companies remained the dominant customer type across the market, reaching USD 0.83 billion in 2025 due to their role as primary sponsors of cell therapy clinical trials and commercial programs. Based on research conducted by Next Move Strategy Consulting, we found that CDMOs represent the fastest-growing customer category at a 27.5% CAGR from 2026 to 2035, reflecting increased outsourcing of cell therapy manufacturing and associated logistics coordination.

Growth Opportunities

Our analysis shows that three forward-looking opportunities stand out for stakeholders positioning within the flexibility platform market over the 2026-2035 forecast period.

How Can Orchestration Software Platforms Unlock Value for Biopharma Customers?

Orchestration and visibility software presents a whitespace opportunity for logistics providers serving biopharma customers managing complex, multi-site chain of custody requirements. Providers that commercialize integrated software platforms combining chain of identity tracking with physical logistics execution stand to capture recurring subscription revenue as commercial-stage therapy volumes scale across global distribution networks.

Where Does Patient Access Services Create New Demand Among Hospital Customers?

Hospitals and treatment centers represent an underpenetrated opportunity for providers offering direct-to-patient and hub services logistics models. Providers that develop standardized site onboarding and reimbursement support capabilities can secure long-term contracts with hospital networks, benefiting from recurring administration-stage logistics volume as commercial cell therapy adoption expands beyond specialized treatment centers.

How Can Allogeneic-Ready Cold Chain Infrastructure Benefit CDMOs and Manufacturers?

CDMOs and manufacturers scaling allogeneic therapy production create an opportunity for providers offering frozen and refrigerated storage infrastructure suited to off-the-shelf cell therapy distribution. Early movers that build multi-lot batch distribution capability can differentiate with manufacturers pursuing simplified, less patient-specific logistics models compared with autologous therapy programs.

SUPPLY CHAIN STRUCTURE OF THE CELL THERAPY LOGISTICS MARKET

The cell therapy logistics market supply chain begins with donor cell collection, processing, cryopreservation, specialized packaging, and cold chain preparation under stringent quality and regulatory controls. Advanced logistics providers then manage cryogenic transportation, real-time shipment monitoring, and delivery to biopharmaceutical manufacturers, hospitals, and treatment centers. Post-delivery services, including shipment validation, temperature excursion management, and documentation, ensure product integrity, traceability, and compliance throughout the cell therapy lifecycle.

Regional Outlook

Geographic Performance Snapshot

Source: www.nextmsc.com

North America Cell Therapy Logistics Market Outlook

North America leads the cell therapy logistics market with the largest concentration of approved CAR-T programs and established cryogenic cold chain infrastructure. We observed that the U.S. Food and Drug Administration's expanding approval list for cellular therapies sustains demand for logistics providers capable of scaling from clinical to commercial distribution. Technology adoption remains advanced, with orchestration software and quality certification gaining share across the region's mature cell therapy logistics ecosystem.

Europe Cell Therapy Logistics Market Outlook

Europe's cell therapy logistics market reflects a maturing landscape shaped by an expanding European Medicines Agency-approved cell therapy pipeline and centralized manufacturing hub development. Our findings suggest that logistics providers across the UK, Germany, and France are investing in regional supply chain centers to reduce cross-border transit times for time-critical shipments. Technology adoption favors providers with proven chain of custody documentation capability, supported by growing regulatory harmonization across the European Union.

Asia-Pacific Cell Therapy Logistics Market Outlook

Asia-Pacific is the fastest-growing cell therapy logistics market region, propelled by rapid clinical trial growth and expanding domestic cell therapy manufacturing capacity across China, India, and Japan. We found that regulatory frameworks remain less harmonized than in North America or Europe, giving logistics providers flexibility to scale rapidly across emerging clinical trial markets. Technology adoption is accelerating as regional biopharma companies and CDMOs expand cryogenic storage and transport infrastructure.

Middle East & Africa Cell Therapy Logistics Market Outlook

The cell therapy logistics market in Middle East & Africa is expanding as Gulf Cooperation Council economies invest in specialty pharmaceutical import infrastructure and hospital network capability. Our analysis shows that Saudi Arabia and the UAE are attracting logistics investment tied to national healthcare modernization programs. Regulatory influence remains moderate, while technology adoption is gradually shifting toward imported cold chain logistics platforms as regional hospitals expand advanced therapy treatment capability.

Latin America Cell Therapy Logistics Market Outlook

Latin America's cell therapy logistics market is supported by expanding clinical trial activity and growing biopharma import demand across Brazil and Argentina. We observed that regulatory frameworks remain less developed than in North America or Europe, though national healthcare systems are gradually building capacity to support advanced therapy distribution. Technology adoption remains centered on clinical trial logistics, with competitive intensity increasing as global providers expand regional distribution partnerships.

U.S. Cell Therapy Logistics Market

Based on our estimates, the U.S. market was valued at approximately USD 0.64 billion in 2025 and is projected to reach USD 4.61 billion by 2035, growing at a 21.9% CAGR. Demand is anchored by the largest concentration of FDA-approved cell therapy programs and established cryogenic logistics infrastructure. Technology penetration favors orchestration software and ISO-certified providers, and competitive intensity remains high among established logistics groups serving major biopharma sponsors.

Canada Cell Therapy Logistics Market

The market in Canada reached roughly USD 0.08 billion in 2025 and is forecast to hit USD 0.63 billion by 2035 at a 23.6% CAGR. Demand structure mirrors U.S. clinical and commercial cell therapy distribution patterns, while Canadian regulatory alignment with U.S. frameworks supports cross-border logistics coordination. Technology penetration is rising as hospitals request integrated visibility platforms, with competitive intensity moderate given reliance on cross-border logistics providers.

UK Cell Therapy Logistics Market

As per our estimate, the UK market stood at about USD 0.11 billion in 2025, advancing toward USD 0.90 billion by 2035 at a 23.0% CAGR. Demand is driven by an established cell and gene therapy clinical trial base and growing commercial approvals following UK regulatory authorization. Regulatory influence from national health service procurement standards is notable, and technology adoption favors providers with proven chain of custody software given the concentration of specialized UK treatment centers.

Germany Cell Therapy Logistics Market

According to our analysis, Germany's market reached close to USD 0.12 billion in 2025 and is expected to hit USD 1.02 billion by 2035, growing at a 23.6% CAGR. Demand is supported by Germany's large biopharma manufacturing base and expanding CDMO cell therapy production capacity. Regulatory influence is well established under EMA guidance, technology penetration is advanced, and competitive intensity remains high among logistics providers serving German biopharma and CDMO customers.

France Cell Therapy Logistics Market

Based on our estimates, France's market reached approximately USD 0.07 billion in 2025, projected to climb to USD 0.57 billion by 2035 at a 23.2% CAGR. Demand is supported by France's growing cell therapy clinical trial base and Cryoport's Global Supply Chain Center launch planned for its Paris facility. Regulatory influence from EMA and national health authority rules is notable, and competitive intensity remains high given the concentration of established logistics providers.

China Cell Therapy Logistics Market

The market in China stood at roughly USD 0.12 billion in 2025 and is forecast to reach USD 1.58 billion by 2035, registering a 29.9% CAGR. Demand is fueled by rapid expansion of domestic cell therapy clinical trials and growing CDMO manufacturing capacity. Regulatory influence is increasing gradually as national drug regulators expand cell therapy approval pathways, technology penetration is accelerating, and competitive intensity remains elevated among both domestic and multinational logistics providers.

India Cell Therapy Logistics Market

As per our estimate, India's market was valued at about USD 0.06 billion in 2025, projected to reach USD 1.02 billion by 2035 at a 33.6% CAGR, the fastest among covered countries. Demand structure reflects rapidly expanding clinical trial activity and growing academic and hospital-led cell therapy research programs. Regulatory influence remains developing, while technology penetration is rising quickly as logistics providers localize cold chain infrastructure to serve India's growing clinical trial base.

Japan Cell Therapy Logistics Market

According to our analysis, Japan's market reached close to USD 0.08 billion in 2025 and is expected to hit USD 0.86 billion by 2035, growing at a 26.2% CAGR. Demand is supported by Japan's early regulatory pathway for regenerative medicine products and expanding domestic cell therapy approvals. Regulatory influence is well established, technology penetration is advanced among domestic logistics providers, and competitive intensity remains high among long-standing regional specialists.

South Korea Cell Therapy Logistics Market

Based on our estimates, South Korea's market stood at approximately USD 0.05 billion in 2025, forecast to reach USD 0.66 billion by 2035 at a 28.9% CAGR. Demand structure benefits from the country's expanding cell and gene therapy manufacturing investment and growing clinical trial activity. Technology penetration is high, with domestic biopharma companies adopting integrated orchestration platforms, and competitive intensity remains pronounced amid rapid market entry by global providers.

Australia Cell Therapy Logistics Market

The cell therapy logistics market in Australia reached about USD 0.03 billion in 2025 and is projected to reach USD 0.36 billion by 2035, expanding at a 27.2% CAGR. Demand is supported by growing clinical trial activity and Australia's established biotech research base. Regulatory influence stems from Therapeutic Goods Administration guidance, while technology adoption favors providers supporting long-haul cryogenic transport amid rising competitive intensity.

UAE Cell Therapy Logistics Market

As per our estimate, the UAE market was valued near USD 0.03 billion in 2025, projected to reach USD 0.33 billion by 2035 at a 26.0% CAGR. Demand structure is shaped by the UAE's role as a regional healthcare and pharmaceutical import hub. Regulatory influence remains moderate, technology penetration is improving through imported cold chain logistics platforms, and competitive intensity is rising as hospitals expand advanced therapy treatment programs to serve Gulf markets.

Saudi Arabia Cell Therapy Logistics Market

According to our analysis, Saudi Arabia's market reached roughly USD 0.03 billion in 2025 and is expected to hit USD 0.34 billion by 2035, growing at a 28.1% CAGR. Demand is driven by national healthcare modernization investment and expanding hospital network capability for advanced therapies. Regulatory influence is developing under national health ministry guidelines, and technology penetration is advancing as domestic hospitals scale cell therapy treatment programs.

South Africa Cell Therapy Logistics Market

Based on our estimates, South Africa's market stood at about USD 0.01 billion in 2025, forecast to reach USD 0.14 billion by 2035 at a 26.1% CAGR. Demand structure reflects a developing specialty healthcare infrastructure program addressing limited advanced therapy treatment capacity across the national hospital network. Regulatory influence remains moderate, technology penetration is gradually improving, and competitive intensity is limited given reliance on imported logistics services from Europe and North America.

Brazil Cell Therapy Logistics Market

The market in Brazil reached approximately USD 0.03 billion in 2025 and is projected to reach USD 0.38 billion by 2035, registering a 27.4% CAGR. Demand is underpinned by Brazil's expanding clinical trial base and growing biopharma import activity. Regulatory influence stems from national health regulatory agency oversight, technology penetration favors clinical trial logistics platforms, and competitive intensity remains moderate among regional logistics integrators.

Argentina Cell Therapy Logistics Market

As per our estimate, Argentina's market was valued near USD 0.01 billion in 2025, projected to reach USD 0.16 billion by 2035 at a 28.6% CAGR. Demand structure is supported by steady clinical trial and biopharma import activity despite macroeconomic volatility. Regulatory influence remains limited, technology penetration is modest, and competitive intensity is centered on a small number of regional distributors serving domestic hospital networks.

Competitive Landscape

We observed that the cell therapy logistics market features a moderately consolidated competitive landscape, with global integrated logistics groups competing alongside specialized cell and gene therapy logistics providers on cold chain expertise, orchestration software, and quality certification.

Key Takeaways

Source: www.nextmsc.com

How Do Companies Compete in the Cell Therapy Logistics Market?

Companies compete primarily on cryogenic handling expertise, chain of custody software integration, and global network reach across the industry. Specialized providers such as Cryoport and TrakCel leverage purpose-built cell and gene therapy platforms to serve biopharma sponsors, while global integrated logistics groups such as FedEx and Kuehne + Nagel compete on established international transport networks and existing pharmaceutical logistics infrastructure.

Which Competitive Archetypes Dominate the Cell Therapy Logistics Market?

Two archetypes dominate the market: specialized cell and gene therapy logistics providers offering purpose-built cryogenic infrastructure and orchestration software, and diversified global logistics groups offering broad pharmaceutical cold chain capability. Cryoport and TrakCel exemplify the specialized archetype through dedicated cell therapy platforms, while UPS and DHL exemplify the diversified archetype leveraging existing global transport networks.

How Are Companies Differentiating Through Innovation in Cell Therapy Logistics?

Innovation and differentiation strategy increasingly center on cryogenic packaging advancement and software-driven chain of custody automation. Cryoport's Cryoport Express Cryogenic HV3 Shipping System and its ISO 21973:2020 certification both signal a shift toward standardized, technology-enabled cold chain execution. Our analysis shows that providers unable to demonstrate credible chain of custody documentation risk exclusion from biopharma request-for-proposal shortlists for commercial-stage programs.

What M&A and Expansion Activity Is Shaping the Cell Therapy Logistics Market?

Mergers, acquisitions, and geographic expansion continue to consolidate specialized capabilities within the industry. Cryoport's continued build-out of regional supply chain centers, including its planned Paris and Santa Ana facilities, illustrates how established providers pursue geographic expansion to support commercial-stage distribution, while software integration partnerships such as Biocair and TrakCel demonstrate consolidation of physical and digital logistics capability.

Key Market Players

Our assessment indicates that the following 20 companies are actively shaping cold chain innovation, orchestration software capability, and global distribution reach within the cell therapy logistics market.

• Cryoport, Inc.

• Cencora, Inc.

• United Parcel Service, Inc.

• Deutsche Post AG

• FedEx Corporation

• Kuehne + Nagel International AG

• Thermo Fisher Scientific Inc.

• McKesson Corporation

• Cardinal Health, Inc.

• DSV A/S

• CEVA Logistics

• PCI Pharma Services

• Almac Group Limited

• Biocair International Ltd

• Arvato SE

• Azenta, Inc.

• Yusen Logistics Co., Ltd.

• Oximio Ltd.

• Yourway Transport Inc.

• TrakCel Ltd.

Latest Developments

We found that recent developments within the flexibility platform market are concentrated on AI-driven orchestration partnerships and multi-market utility licensing, reflecting the industry's broader scaling transition.

Source: www.nextmsc.com

Investment Opportunities

What Capital Inflows Are Targeting the Cell Therapy Logistics Market?

Capital inflows into the cell therapy logistics market are increasingly directed toward regional supply chain center expansion and orchestration software development. Cryoport's raised full-year 2026 revenue guidance to between USD 192 million and USD 196 million reflects sustained investor confidence in commercial-stage cell therapy logistics growth. We observed that investors favor providers demonstrating validated commercial-stage revenue growth, viewing quality certification as a proxy for long-term biopharma contract retention.

How Is Infrastructure Investment Supporting Cell Therapy Logistics Scaling?

Infrastructure investment is expanding regional supply chain centers to support growing commercial-stage distribution volumes. Cryoport's planned Global Supply Chain Center launches in Paris, France and Santa Ana, California during 2026 illustrate how providers are building out geographically distributed cryogenic storage and transport hubs. Our findings suggest that this infrastructure expansion is critical to supporting the shorter transit times required for viable cell therapy distribution.

What ESG Considerations Are Shaping Cell Therapy Logistics Investment Decisions?

Environmental, social, and governance considerations are relevant to investment decisions across the industry, with sustainable cryogenic packaging and liquid nitrogen dependency reduction as emerging criteria. MVE Biological Solutions' Fusion 800 Series self-sustaining cryogenic freezer, which eliminates continuous liquid nitrogen supply feed requirements, reflects this sustainability focus. We found that investors increasingly consider packaging sustainability and patient access equity as governance indicators alongside data security and chain of custody compliance.

Key Benefits for Stakeholders

How Does This Report Benefit Enterprise and Industry Leaders?

Enterprise and industry leaders gain access to validated segmentation, competitive benchmarking, and regional demand forecasts that support logistics sourcing and portfolio decisions across the cell therapy logistics industry. Our analysis shows that detailed service offering, temperature regime, and customer type breakdowns help procurement teams align specifications with regulatory and chain of custody requirements while identifying underserved segments for portfolio expansion.

How Does This Report Benefit Investors and Financial Analysts?

Investors and financial analysts benefit from consistent, single-point market size and CAGR estimates that support valuation and capital-allocation decisions across the cell therapy logistics supply chain. We observed that the report's regional and segment-level growth differentials help identify which logistics providers are best positioned to capture above-market growth in commercial-stage and software orchestration categories through 2035.

How Does This Report Benefit Technology Vendors and Product Teams?

Technology vendors and product teams gain insight into emerging platform requirements, including chain of custody orchestration and cryogenic packaging innovation, that are reshaping the industry. Our findings suggest that this analysis helps product teams prioritize development roadmaps around software integration and quality certification increasingly required by biopharma request-for-proposal processes.

Key Market Segments

By Service Offering

• Transport Services

  • Inbound Collection

  • Interfacility Transfer

  • Outbound Distribution

  • Reverse Logistics

• Storage Services

  • Cryogenic Storage

  • Frozen Storage

  • Refrigerated Storage

  • Ambient Storage

• Packaging And Conditioning Services

  • Shipper Rental

  • Pack-Out and Kitting

  • Repacking And Relabeling

• Control Tower Services

  • Chain Of Identity

  • Chain Of Custody

  • Track And Trace

  • Exception Management

  • Route Planning

• Patient Access Services

  • Hub Services

  • Site Onboarding

  • Direct To Patient

  • Reimbursement Support

• Quality And Compliance Services

  • Lane Validation

  • SOP Design

  • Audit Support

  • Regulatory Support

• Software Services

  • Orchestration Platforms

  • Visibility Platforms

  • Inventory Management

  • QMS Platforms

By Therapy Modality

• Autologous

• Allogeneic

By Workflow Stage

• Collection

• Manufacturing Transfer

• Distribution

• Administration

• Reverse Logistics

By Temperature Regime

• Ambient

• Refrigerated

• Frozen

• Cryogenic

By Commercial Stage

• Clinical

• Commercial

By Customer Type

• Biopharma

• CDMO

• Hospital

• Academic

• CRO

By Sales Channel

• Direct Contract

• Partner Network

• Embedded Platform

By Region

• North America: U.S., Canada, Mexico

• Europe: UK, Germany, France, Italy, Spain, Sweden, Denmark, Finland, Netherlands, Rest of Europe

• Asia-Pacific: China, India, Japan, South Korea, Taiwan, Indonesia,Vietnam, Australia, Philippines, Malaysia, Rest of APAC

• Middle East & Africa: Saudi Arabia, UAE, Egypt, Israel, Turkey, Nigeria, South Africa, Rest of MEA

• Latin America: Brazil, Argentina, Chile, Colombia, Rest of LATAM

Conclusion and Recommendations

What Is the Long-Term Outlook for the Cell Therapy Logistics Market?

The long-term outlook for the market remains strongly positive, with global revenue projected to grow more than ninefold from USD 1.81 billion in 2025 to USD 16.95 billion by 2035 at a 25.05% CAGR. We observed that sustained regulatory approvals, expanding commercial-stage distribution, and growing orchestration software adoption will continue underpinning demand across biopharma, CDMO, and hospital applications through the forecast period.

What Strategic Positioning Should Cell Therapy Logistics Suppliers Pursue?

Suppliers should prioritize integrated chain of custody software capability and cryogenic packaging innovation while pursuing regional supply chain center expansion to secure long-term biopharma contracts. Our assessment indicates that providers investing early in quality certification and commercial-stage distribution infrastructure will be best positioned to capture premium pricing within the cell therapy logistics market.

How Attractive Is the Cell Therapy Logistics Market for New Investment?

The cell therapy logistics industry presents a highly attractive investment case, supported by a USD 14.68 billion absolute dollar opportunity between 2026 and 2035 and above-average growth in Asia-Pacific and commercial-stage distribution categories. We found that investment attractiveness is highest for providers combining validated chain of custody software with scaled cryogenic infrastructure.

What Market Shifts and Key Risks Should Stakeholders Monitor?

Stakeholders should monitor high logistics cost structures for smaller developers, limited standardization of chain of custody protocols across jurisdictions, and specialized workforce shortages in emerging regions as key risks to the cell therapy logistics market. Our analysis shows that suppliers unable to demonstrate scalable, standardized chain of custody documentation risk losing biopharma contracts to competitors with proven commercial-stage delivery credentials.

What Are the Key Growth Pathways for the Cell Therapy Logistics Market?

Key growth pathways include expanding commercial-stage distribution networks, scaling orchestration software platforms, and deepening patient access services for hospital and direct-to-patient delivery models. Next Move Strategy Consulting's analysis indicates that suppliers pursuing these pathways while maintaining cost competitiveness in standard clinical trial logistics categories will be best positioned to capture the cell therapy logistics market's projected growth through 2035.